A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Registration Number
- NCT06623422
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 680
The main inclusion criteria include but are not limited to the following:
- Has histologically/cytologically confirmed diagnosis of previously untreated and pathologically confirmed resectable Stage II, IIIA, or IIIB (N2) non-small cell lung cancer (NSCLC) [American Joint Committee on Cancer (AJCC) 8th Edition]
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before the first dose of study intervention
- Participants who have not achieved a pathological complete response (pCR) following completion of neoadjuvant chemotherapy and pembrolizumab followed by surgery will be eligible
- Confirmation that epidermal growth factor receptor (EGFR)-directed therapy is not indicated as primary therapy (documentation of absence of tumor-activating EGFR mutations [eg, DEL19 or L858R])
- Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART)
- Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization
- Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening
The main exclusion criteria include but are not limited to the following:
- Diagnosis of SCLC or, for mixed tumors, presence of small cell elements, or has a neuroendocrine tumor with large-cell components, or a sarcomatoid carcinoma, or a pancoast tumor
- Documentation by local test report indicating presence of anaplastic lymphoma kinase (ALK) gene rearrangements
- Received prior neoadjuvant therapy for their current NSCLC diagnosis
- Received prior therapy with an anti-programmed cell death 1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti-programmed cell-death ligand 2 (PD-L2) agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein [CTLA-4], OX-40, CD137)
- Received prior systemic anticancer therapy including investigational agents other than what is specified in this protocol
- Received prior treatment with a cancer vaccine
- Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids
- Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Pembrolizumab + Intismeran autogene Carboplatin For neoadjuvant treatment, participants will receive pembrolizumab 200 mg via intravenous (IV) infusion every 3-week cycle for up to 4 cycles PLUS background chemotherapy via IV infusion (cisplatin 75 mg/m\^2 or carboplatin area under the curve \[AUC\] 5 or 6 mg/mL/min, pemetrexed 500 mg/m\^2, gemcitabine 1000 mg/m\^2, paclitaxel 175 mg/m\^2 or 200 mg/m\^2 given at a dose and combination per investigator's choice) every 3-week cycle for up to 4 cycles (total neoadjuvant treatment duration of up to \~12 weeks). After surgical resection, for adjuvant treatment, participants will receive pembrolizumab 400 mg via IV infusion every 6-week cycle for up to 7 cycles PLUS intismeran autogene 1 mg via intramuscular (IM) injection every 3 weeks for up to 9 doses (total adjuvant treatment duration of up to \~42 weeks). Pembrolizumab + Intismeran autogene Pemetrexed For neoadjuvant treatment, participants will receive pembrolizumab 200 mg via intravenous (IV) infusion every 3-week cycle for up to 4 cycles PLUS background chemotherapy via IV infusion (cisplatin 75 mg/m\^2 or carboplatin area under the curve \[AUC\] 5 or 6 mg/mL/min, pemetrexed 500 mg/m\^2, gemcitabine 1000 mg/m\^2, paclitaxel 175 mg/m\^2 or 200 mg/m\^2 given at a dose and combination per investigator's choice) every 3-week cycle for up to 4 cycles (total neoadjuvant treatment duration of up to \~12 weeks). After surgical resection, for adjuvant treatment, participants will receive pembrolizumab 400 mg via IV infusion every 6-week cycle for up to 7 cycles PLUS intismeran autogene 1 mg via intramuscular (IM) injection every 3 weeks for up to 9 doses (total adjuvant treatment duration of up to \~42 weeks). Pembrolizumab + Intismeran autogene Gemcitabine For neoadjuvant treatment, participants will receive pembrolizumab 200 mg via intravenous (IV) infusion every 3-week cycle for up to 4 cycles PLUS background chemotherapy via IV infusion (cisplatin 75 mg/m\^2 or carboplatin area under the curve \[AUC\] 5 or 6 mg/mL/min, pemetrexed 500 mg/m\^2, gemcitabine 1000 mg/m\^2, paclitaxel 175 mg/m\^2 or 200 mg/m\^2 given at a dose and combination per investigator's choice) every 3-week cycle for up to 4 cycles (total neoadjuvant treatment duration of up to \~12 weeks). After surgical resection, for adjuvant treatment, participants will receive pembrolizumab 400 mg via IV infusion every 6-week cycle for up to 7 cycles PLUS intismeran autogene 1 mg via intramuscular (IM) injection every 3 weeks for up to 9 doses (total adjuvant treatment duration of up to \~42 weeks). Pembrolizumab + Intismeran autogene Paclitaxel For neoadjuvant treatment, participants will receive pembrolizumab 200 mg via intravenous (IV) infusion every 3-week cycle for up to 4 cycles PLUS background chemotherapy via IV infusion (cisplatin 75 mg/m\^2 or carboplatin area under the curve \[AUC\] 5 or 6 mg/mL/min, pemetrexed 500 mg/m\^2, gemcitabine 1000 mg/m\^2, paclitaxel 175 mg/m\^2 or 200 mg/m\^2 given at a dose and combination per investigator's choice) every 3-week cycle for up to 4 cycles (total neoadjuvant treatment duration of up to \~12 weeks). After surgical resection, for adjuvant treatment, participants will receive pembrolizumab 400 mg via IV infusion every 6-week cycle for up to 7 cycles PLUS intismeran autogene 1 mg via intramuscular (IM) injection every 3 weeks for up to 9 doses (total adjuvant treatment duration of up to \~42 weeks). Pembrolizumab + Intismeran autogene Pembrolizumab For neoadjuvant treatment, participants will receive pembrolizumab 200 mg via intravenous (IV) infusion every 3-week cycle for up to 4 cycles PLUS background chemotherapy via IV infusion (cisplatin 75 mg/m\^2 or carboplatin area under the curve \[AUC\] 5 or 6 mg/mL/min, pemetrexed 500 mg/m\^2, gemcitabine 1000 mg/m\^2, paclitaxel 175 mg/m\^2 or 200 mg/m\^2 given at a dose and combination per investigator's choice) every 3-week cycle for up to 4 cycles (total neoadjuvant treatment duration of up to \~12 weeks). After surgical resection, for adjuvant treatment, participants will receive pembrolizumab 400 mg via IV infusion every 6-week cycle for up to 7 cycles PLUS intismeran autogene 1 mg via intramuscular (IM) injection every 3 weeks for up to 9 doses (total adjuvant treatment duration of up to \~42 weeks). Pembrolizumab + Intismeran autogene Cisplatin For neoadjuvant treatment, participants will receive pembrolizumab 200 mg via intravenous (IV) infusion every 3-week cycle for up to 4 cycles PLUS background chemotherapy via IV infusion (cisplatin 75 mg/m\^2 or carboplatin area under the curve \[AUC\] 5 or 6 mg/mL/min, pemetrexed 500 mg/m\^2, gemcitabine 1000 mg/m\^2, paclitaxel 175 mg/m\^2 or 200 mg/m\^2 given at a dose and combination per investigator's choice) every 3-week cycle for up to 4 cycles (total neoadjuvant treatment duration of up to \~12 weeks). After surgical resection, for adjuvant treatment, participants will receive pembrolizumab 400 mg via IV infusion every 6-week cycle for up to 7 cycles PLUS intismeran autogene 1 mg via intramuscular (IM) injection every 3 weeks for up to 9 doses (total adjuvant treatment duration of up to \~42 weeks). Pembrolizumab + Intismeran autogene Intismeran autogene For neoadjuvant treatment, participants will receive pembrolizumab 200 mg via intravenous (IV) infusion every 3-week cycle for up to 4 cycles PLUS background chemotherapy via IV infusion (cisplatin 75 mg/m\^2 or carboplatin area under the curve \[AUC\] 5 or 6 mg/mL/min, pemetrexed 500 mg/m\^2, gemcitabine 1000 mg/m\^2, paclitaxel 175 mg/m\^2 or 200 mg/m\^2 given at a dose and combination per investigator's choice) every 3-week cycle for up to 4 cycles (total neoadjuvant treatment duration of up to \~12 weeks). After surgical resection, for adjuvant treatment, participants will receive pembrolizumab 400 mg via IV infusion every 6-week cycle for up to 7 cycles PLUS intismeran autogene 1 mg via intramuscular (IM) injection every 3 weeks for up to 9 doses (total adjuvant treatment duration of up to \~42 weeks). Pembrolizumab + Placebo Pembrolizumab For neoadjuvant treatment, participants will receive pembrolizumab 200 mg via IV infusion every 3-week cycle for up to 4 cycles PLUS background chemotherapy via IV infusion (cisplatin 75 mg/m\^2 or carboplatin AUC 5 or 6 mg/mL/min, pemetrexed 500 mg/m\^2, gemcitabine 1000 mg/m\^2, paclitaxel 175 mg/m\^2 or 200 mg/m\^2 given at a dose and combination per investigator's choice) every 3-week cycle for up to 4 cycles (total neoadjuvant treatment duration of up to \~12 weeks). After surgical resection, for adjuvant treatment, participants will receive pembrolizumab 400 mg via IV infusion every 6-week cycle for up to 7 cycles PLUS matching placebo via IM injection every 3 weeks for up to 9 doses (total adjuvant treatment duration of up to \~42 weeks). Pembrolizumab + Placebo Cisplatin For neoadjuvant treatment, participants will receive pembrolizumab 200 mg via IV infusion every 3-week cycle for up to 4 cycles PLUS background chemotherapy via IV infusion (cisplatin 75 mg/m\^2 or carboplatin AUC 5 or 6 mg/mL/min, pemetrexed 500 mg/m\^2, gemcitabine 1000 mg/m\^2, paclitaxel 175 mg/m\^2 or 200 mg/m\^2 given at a dose and combination per investigator's choice) every 3-week cycle for up to 4 cycles (total neoadjuvant treatment duration of up to \~12 weeks). After surgical resection, for adjuvant treatment, participants will receive pembrolizumab 400 mg via IV infusion every 6-week cycle for up to 7 cycles PLUS matching placebo via IM injection every 3 weeks for up to 9 doses (total adjuvant treatment duration of up to \~42 weeks). Pembrolizumab + Placebo Carboplatin For neoadjuvant treatment, participants will receive pembrolizumab 200 mg via IV infusion every 3-week cycle for up to 4 cycles PLUS background chemotherapy via IV infusion (cisplatin 75 mg/m\^2 or carboplatin AUC 5 or 6 mg/mL/min, pemetrexed 500 mg/m\^2, gemcitabine 1000 mg/m\^2, paclitaxel 175 mg/m\^2 or 200 mg/m\^2 given at a dose and combination per investigator's choice) every 3-week cycle for up to 4 cycles (total neoadjuvant treatment duration of up to \~12 weeks). After surgical resection, for adjuvant treatment, participants will receive pembrolizumab 400 mg via IV infusion every 6-week cycle for up to 7 cycles PLUS matching placebo via IM injection every 3 weeks for up to 9 doses (total adjuvant treatment duration of up to \~42 weeks). Pembrolizumab + Placebo Pemetrexed For neoadjuvant treatment, participants will receive pembrolizumab 200 mg via IV infusion every 3-week cycle for up to 4 cycles PLUS background chemotherapy via IV infusion (cisplatin 75 mg/m\^2 or carboplatin AUC 5 or 6 mg/mL/min, pemetrexed 500 mg/m\^2, gemcitabine 1000 mg/m\^2, paclitaxel 175 mg/m\^2 or 200 mg/m\^2 given at a dose and combination per investigator's choice) every 3-week cycle for up to 4 cycles (total neoadjuvant treatment duration of up to \~12 weeks). After surgical resection, for adjuvant treatment, participants will receive pembrolizumab 400 mg via IV infusion every 6-week cycle for up to 7 cycles PLUS matching placebo via IM injection every 3 weeks for up to 9 doses (total adjuvant treatment duration of up to \~42 weeks). Pembrolizumab + Placebo Gemcitabine For neoadjuvant treatment, participants will receive pembrolizumab 200 mg via IV infusion every 3-week cycle for up to 4 cycles PLUS background chemotherapy via IV infusion (cisplatin 75 mg/m\^2 or carboplatin AUC 5 or 6 mg/mL/min, pemetrexed 500 mg/m\^2, gemcitabine 1000 mg/m\^2, paclitaxel 175 mg/m\^2 or 200 mg/m\^2 given at a dose and combination per investigator's choice) every 3-week cycle for up to 4 cycles (total neoadjuvant treatment duration of up to \~12 weeks). After surgical resection, for adjuvant treatment, participants will receive pembrolizumab 400 mg via IV infusion every 6-week cycle for up to 7 cycles PLUS matching placebo via IM injection every 3 weeks for up to 9 doses (total adjuvant treatment duration of up to \~42 weeks). Pembrolizumab + Placebo Paclitaxel For neoadjuvant treatment, participants will receive pembrolizumab 200 mg via IV infusion every 3-week cycle for up to 4 cycles PLUS background chemotherapy via IV infusion (cisplatin 75 mg/m\^2 or carboplatin AUC 5 or 6 mg/mL/min, pemetrexed 500 mg/m\^2, gemcitabine 1000 mg/m\^2, paclitaxel 175 mg/m\^2 or 200 mg/m\^2 given at a dose and combination per investigator's choice) every 3-week cycle for up to 4 cycles (total neoadjuvant treatment duration of up to \~12 weeks). After surgical resection, for adjuvant treatment, participants will receive pembrolizumab 400 mg via IV infusion every 6-week cycle for up to 7 cycles PLUS matching placebo via IM injection every 3 weeks for up to 9 doses (total adjuvant treatment duration of up to \~42 weeks). Pembrolizumab + Placebo Placebo For neoadjuvant treatment, participants will receive pembrolizumab 200 mg via IV infusion every 3-week cycle for up to 4 cycles PLUS background chemotherapy via IV infusion (cisplatin 75 mg/m\^2 or carboplatin AUC 5 or 6 mg/mL/min, pemetrexed 500 mg/m\^2, gemcitabine 1000 mg/m\^2, paclitaxel 175 mg/m\^2 or 200 mg/m\^2 given at a dose and combination per investigator's choice) every 3-week cycle for up to 4 cycles (total neoadjuvant treatment duration of up to \~12 weeks). After surgical resection, for adjuvant treatment, participants will receive pembrolizumab 400 mg via IV infusion every 6-week cycle for up to 7 cycles PLUS matching placebo via IM injection every 3 weeks for up to 9 doses (total adjuvant treatment duration of up to \~42 weeks).
- Primary Outcome Measures
Name Time Method Disease-Free Survival (DFS) Up to ~97 months DFS is defined as the time from randomization to any recurrence (local, locoregional, regional or distant), occurrence of new primary NSCLC, as assessed by the investigator, or death due to any cause, whichever occurs first.
- Secondary Outcome Measures
Name Time Method Overall Survival (OS) Up to ~129 months OS is defined as the time from randomization to death due to any cause.
Distant Metastasis-Free Survival (DMFS) Up to ~129 months DMFS is defined as the time from randomization to the first diagnosis of a distant metastasis as assessed by the investigator, or death due to any cause, whichever occurs first. Distant metastasis refers to cancer that has spread from the original (primary) tumor and beyond local tissues and lymph nodes to distant organs or distant lymph nodes.
Disease-Free Survival 2 (DFS2) Up to ~129 months DFS2 is defined as the time from randomization to subsequent recurrence or disease progression after initiation of next-line anticancer therapy as assessed by the investigator, or death due to any cause, whichever occurs first.
Lung Cancer Specific Survival (LCSS) Up to ~129 months LCSS is defined as the time from randomization to death due to lung cancer specifically as assessed by the investigator.
Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Baseline and up to ~129 months The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" will be scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores will be standardized, so that scores range from 0 to 100. Higher scores indicate a better overall health status. The change from baseline in global health status/quality of life (EORTC QLQ-C30 Items 29 and 30) combined score will be presented.
Change from Baseline in the EORTC QLQ-C30 Physical Functioning (Items 1-5) Baseline and up to ~129 months The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning will be scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores will be standardized, so that scores range from 0 to 100. Higher scores indicate a worse level of physical functioning. The change from baseline in physical functioning (EORTC QLQ-C30 Items 1-5) combined score will be presented.
Change from Baseline in the EORTC QLQ-C30 Role Functioning (Items 6 and 7) Baseline and up to ~129 months The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "Were you limited in doing either your work or other daily activities during the past week?" and " Were you limited in pursuing your hobbies or other leisure time activities during the past week?" will be scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate a worse level of role functioning. Change from baseline in the role functioning (EORTC QLQ-C30 Items 6 and 7) combined score will be presented.
Number of participants with ≥1 adverse event (AE) Up to ~129 months An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Number of participants discontinuing from study therapy due to AE(s) Up to ~129 months An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Trial Locations
- Locations (79)
Providence St. Jude Medical Center ( Site 0106)
🇺🇸Fullerton, California, United States
Ellis Fischel Cancer Center ( Site 0133)
🇺🇸Columbia, Missouri, United States
Lake Regional Hospital-Cancer Center ( Site 0123)
🇺🇸Osage Beach, Missouri, United States
UCHealth Memorial Hospital Central ( Site 0125)
🇺🇸Colorado Springs, Colorado, United States
Beacon Cancer Care ( Site 0127)
🇺🇸Post Falls, Idaho, United States
The University of Chicago Medical Center ( Site 0118)
🇺🇸Chicago, Illinois, United States
Montefiore Medical Center ( Site 0160)
🇺🇸Bronx, New York, United States
Hematology-Oncology Associates of CNY ( Site 0164)
🇺🇸East Syracuse, New York, United States
Icahn School of Medicine at Mount Sinai ( Site 0116)
🇺🇸New York, New York, United States
Memorial Sloan Kettering Cancer Center ( Site 0137)
🇺🇸New York, New York, United States
University of Cincinnati Medical Center ( Site 0119)
🇺🇸Cincinnati, Ohio, United States
St. Lukes Hospital and Health Network ( Site 0186)
🇺🇸Bethlehem, Pennsylvania, United States
Thompson Cancer Survival Center ( Site 0168)
🇺🇸Knoxville, Tennessee, United States
MD Anderson Cancer Center ( Site 0150)
🇺🇸Houston, Texas, United States
The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center ( Site 0148)
🇺🇸Tyler, Texas, United States
CEMIC ( Site 2454)
🇦🇷Caba., Buenos Aires, Argentina
Fundacion Intecnus ( Site 2456)
🇦🇷San Carlos de Bariloche, Rio Negro, Argentina
Centro Médico IPAM ( Site 2452)
🇦🇷Rosario, Santa Fe, Argentina
Instituto Medico Especializado Alexander Fleming ( Site 2457)
🇦🇷Buenos Aires, Argentina
Instituto Oncologico de Cordoba -IONC ( Site 2455)
🇦🇷Cordoba, Argentina
Calvary Mater Newcastle ( Site 2106)
🇦🇺Waratah, New South Wales, Australia
Tasman Oncology Research ( Site 2104)
🇦🇺Southport, Queensland, Australia
Grampians Health ( Site 2101)
🇦🇺Ballarat, Victoria, Australia
One Clinical Research ( Site 2103)
🇦🇺Nedlands, Western Australia, Australia
CRIO - CENTRO REGIONAL INTEGRADO DE ONCOLOGIA ( Site 2502)
🇧🇷Fortaleza, Ceara, Brazil
Liga Norte Riograndense Contra o Cancer ( Site 2513)
🇧🇷Natal, Rio Grande Do Norte, Brazil
Hospital Tacchini ( Site 2506)
🇧🇷Bento Goncalves, Rio Grande Do Sul, Brazil
Hospital de Clínicas de Passo Fundo ( Site 2504)
🇧🇷Passo Fundo, Rio Grande Do Sul, Brazil
Hospital Moinhos de Vento ( Site 2510)
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Instituto de Oncologia Saint Gallen ( Site 2507)
🇧🇷Santa Cruz do Sul, Rio Grande Do Sul, Brazil
Hospital de Amor - Barretos ( Site 2511)
🇧🇷Barretos, Sao Paulo, Brazil
Queen Elizabeth II Health Sciences Centre ( Site 1101)
🇨🇦Halifax, Nova Scotia, Canada
Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 1105)
🇨🇦Kingston, Ontario, Canada
Lakeridge Health ( Site 1107)
🇨🇦Oshawa, Ontario, Canada
McGill University Health Centre ( Site 1103)
🇨🇦Montréal, Quebec, Canada
FALP ( Site 2551)
🇨🇱Santiago., Region M. De Santiago, Chile
Orlandi Oncologia ( Site 2555)
🇨🇱Santiago, Region M. De Santiago, Chile
Clínica RedSalud Vitacura ( Site 2556)
🇨🇱Santiago, Region M. De Santiago, Chile
Bradfordhill ( Site 2552)
🇨🇱Santiago, Region M. De Santiago, Chile
ONCOCENTRO APYS ( Site 2554)
🇨🇱Viña del Mar, Valparaiso, Chile
IMAT S.A.S ( Site 2602)
🇨🇴Monteria, Cordoba, Colombia
FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 2603)
🇨🇴Bogota, Distrito Capital De Bogota, Colombia
Hospital Universitario San Ignacio ( Site 2610)
🇨🇴Bogota, Distrito Capital De Bogota, Colombia
Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia ( Site 2604)
🇨🇴Bogota, Distrito Capital De Bogota, Colombia
Oncologos del Occidente ( Site 2608)
🇨🇴Pereira, Risaralda, Colombia
Fundacion Valle del Lili- CIC ( Site 2601)
🇨🇴Cali, Valle Del Cauca, Colombia
Rambam Health Care Campus ( Site 1603)
🇮🇱Haifa, Israel
Shaare Zedek Medical Center ( Site 1601)
🇮🇱Jerusalem, Israel
Hadassah Medical Center ( Site 1605)
🇮🇱Jerusalem, Israel
Sheba Medical Center ( Site 1602)
🇮🇱Ramat Gan, Israel
National Cancer Center Hospital ( Site 1156)
🇯🇵Chuo, Tokyo, Japan
Tokyo Medical University Hospital ( Site 1157)
🇯🇵Shinjuku, Tokyo, Japan
National Hospital Organization Kyushu Cancer Center ( Site 1167)
🇯🇵Fukuoka, Japan
Fukushima Medical University Hospital ( Site 1151)
🇯🇵Fukushima, Japan
Hiroshima University Hospital ( Site 1165)
🇯🇵Hiroshima, Japan
Wakayama Medical University Hospital ( Site 1163)
🇯🇵Wakayama, Japan
National Cancer Center ( Site 2305)
🇰🇷Goyang-si, Kyonggi-do, Korea, Republic of
The Catholic University of Korea St. Vincent s Hospital ( Site 2301)
🇰🇷Suwonsi, Kyonggi-do, Korea, Republic of
Ajou University Hospital ( Site 2306)
🇰🇷Suwon, Kyonggi-do, Korea, Republic of
Seoul National University Hospital ( Site 2303)
🇰🇷Seoul, Korea, Republic of
Chung Shan Medical University Hospital ( Site 2351)
🇨🇳Taichung, Taiwan
China Medical University Hospital ( Site 2358)
🇨🇳Taichung, Taiwan
National Cheng Kung University Hospital ( Site 2354)
🇨🇳Tainan, Taiwan
Severance Hospital Yonsei University Health System ( Site 2302)
🇰🇷Seoul, Korea, Republic of
Mackay Memorial Hospital ( Site 2355)
🇨🇳Taipei, Taiwan
Samsung Medical Center ( Site 2304)
🇰🇷Seoul, Korea, Republic of
Seoul St. Mary's Hospital ( Site 2307)
🇰🇷Seoul, Korea, Republic of
National Cancer Centre Singapore ( Site 2251)
🇸🇬Singapore, Central Singapore, Singapore
Taipei Medical University Hospital ( Site 2352)
🇨🇳Taipei, Taiwan
Taipei Veterans General Hospital ( Site 2357)
🇨🇳Taipei, Taiwan
Tan Tock Seng Hospital ( Site 2252)
🇸🇬Singapore, Central Singapore, Singapore
Koo Foundation Sun Yat-Sen Cancer Center ( Site 2359)
🇨🇳Taipei, Taiwan
Chang Gung Memorial Hospital ( Site 2361)
🇨🇳Taoyuan, Taiwan
Hacettepe Universite Hastaneleri ( Site 2001)
🇹🇷Sıhhiye, Ankara, Turkey
Namık Kemal University Medical Faculty ( Site 2007)
🇹🇷Tekirdag, Tekirdas, Turkey
Bristol Haematology and Oncology Centre ( Site 2072)
🇬🇧Bristol, Bristol, City Of, United Kingdom
St Bartholomews Hospital ( Site 2052)
🇬🇧London, London, City Of, United Kingdom
Nottingham City Hospital ( Site 2058)
🇬🇧Nottingham, Nottinghamshire, United Kingdom
St James University Hospital ( Site 2055)
🇬🇧Leeds, United Kingdom